scholarly journals Immunogenicity of Inactivated Polio Vaccine with Concurrent Antiviral V-073 Administration in Mice

2011 ◽  
Vol 18 (8) ◽  
pp. 1387-1390 ◽  
Author(s):  
Diana Kouiavskaia ◽  
Marc S. Collett ◽  
Eugenia M. Dragunsky ◽  
Andrey Sarafanov ◽  
Konstantin M. Chumakov
Keyword(s):  
Neutralizing Antibodies ◽  
Inactivated Polio Vaccine ◽  
Polio Vaccine ◽  
Detrimental Impact

ABSTRACTImmunization of mice with inactivated polio vaccine (IPV) with concurrent dosing of poliovirus antiviral V-073 showed no detrimental impact on the elicitation of serum-neutralizing antibodies. A strategy involving coadministration of antiviral V-073 and IPV can be considered for the management of poliovirus incidents.

scholarly journals In-Vitro Inactivation of Sabin-Polioviruses for Development of Safe and Effective Polio Vaccine

Vaccines ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 601
Author(s):  
Asmaa A. Abd-Elghaffar ◽  
Mohamed E. Rashed ◽  
Amal E. Ali ◽  
Magdy A. Amin
Keyword(s):  
Neutralizing Antibodies ◽  
Production Cost ◽  
Inactivation Kinetics ◽  
Free World ◽  
Time Saving ◽  
Inactivated Polio Vaccine ◽  
Polio Vaccine ◽  
D Antigen

After years of global collaboration; we are steps away from a polio-free world. However, the currently conventional inactivated polio vaccine (cIPV) is suboptimal for the post eradication era. cIPV production cost and biosafety hazards hinder its availability and coverage of the global demands. Production of IPV from the attenuated Sabin strains (sIPV) was an ideal solution and scientists work extensively to perfect a safe, effective and affordable sIPV. This study investigated the ability of hydrogen peroxide (H2O2), ascorbic acid (AA) and epigallocatechin-3-gallate (EGCG) as alternatives for Formaldehyde (HCHO) to inactivate Sabin-polioviruses strains for sIPV production. Sabin-polioviruses vaccine strains were individually treated with AA, EGCG or H2O2 and were compared to HCHO. This was investigated by determination of the inactivation kinetics on HEP2C cells, testing of D-antigen preservation by ELISA and the immune response in Wistar rats of the four vaccine preparations. H2O2, AA and EGCG were able to inactivate polioviruses within 24 h while HCHO required 96 h. Significant high D-antigen levels were observed using AA, EGCG and H2O2 compared to HCHO. Rat sera tested for neutralizing antibodies showed comparable results. These findings support the idea of using these inactivating agents as safe and time- saving alternatives for HCHO to produce sIPV.

scholarly journals PREVALENCE OF NEUTRALIZING ANTIBODIES AGAINST POLIOVIRUS 1, 2, AND 3 IN HEALTHCARE PROFESSIONALS AGED 20-50 YEARS

2021 ◽  
Vol 39 ◽  
Author(s):  
José Cassio de Moraes ◽  
Maria Josefa Penon Rujula ◽  
Marcelo Otsuka
Keyword(s):  
Immune Response ◽  
Health Professionals ◽  
Neutralizing Antibodies ◽  
Healthcare Professionals ◽  
Chi Square ◽  
Inactivated Polio Vaccine ◽  
Blood Samples ◽  
Significant Percentage ◽  
Polio Vaccine ◽  
Response Compatible

ABSTRACT Objective: To describe the prevalence of neutralizing antibodies against poliovirus (PV1, PV2, and PV3) in blood samples of healthcare professionals aged 20 to 50 years. Methods: Health professionals who serve children at Darcy Vargas Children’s Hospital and the Department of Pediatrics of Irmandade da Santa Casa de São Paulo. The sample size was calculated at 323 participants. The Mantel-Haenszel chi-square was used to verify differences between groups. The neutralization reaction detected human poliovirus antibodies. For susceptible individuals, vaccination with the inactivated+triple acellular polio vaccine was performed, and neutralizing antibodies were re-dosed after one week. Results: 333 professionals were studied - 92.8% were immune to poliovirus 1, 86.5% to poliovirus 2, and 63.3% to poliovirus 3; 37% had titers less than 1:8 for any serotype, 5;1% had titers below 1:8 for all three. Vaccination with inactivated polio vaccine was performed for susceptible participants, and neutralizing antibodies were dosed after one week, showing increased titers for all polioviruses. Conclusions: Despite the detection of a significant percentage of individuals with low poliovirus antibody titer, the challenge with vaccination demonstrated immune response compatible with poliovirus immunity.

scholarly journals Development of Thermostable Lyophilized Inactivated Polio Vaccine

2014 ◽  
Vol 31 (10) ◽  
pp. 2618-2629 ◽  
Author(s):  
Heleen Kraan ◽  
Paul van Herpen ◽  
Gideon Kersten ◽  
Jean-Pierre Amorij
Keyword(s):  
Inactivated Polio Vaccine ◽  
Polio Vaccine

scholarly journals Advax-CpG Adjuvant Provides Antigen Dose-Sparing and Enhanced Immunogenicity for Inactivated Poliomyelitis Virus Vaccines

Pathogens ◽  
2021 ◽  
Vol 10 (5) ◽  
pp. 500
Author(s):  
Yoshikazu Honda-Okubo ◽  
Jeremy Baldwin ◽  
Nikolai Petrovsky
Keyword(s):  
Neutralizing Antibodies ◽  
Serum Antibody ◽  
Oral Polio Vaccine ◽  
Antigen Dose ◽  
Polio Vaccine ◽  
Antibody Titers ◽  
Dose Sparing ◽  
Sparing Effect ◽  
Eradicate Polio

Global immunization campaigns have resulted in a major decline in the global incidence of polio cases, with wild-type poliovirus remaining endemic in only two countries. Live oral polio vaccine (OPV) played a role in the reduction in polio case numbers; however, the risk of OPV developing into circulating vaccine-derived poliovirus makes it unsuitable for eradication programs. Trivalent inactivated polio virus (TIPV) vaccines which contain formalin-inactivated antigens produced from virulent types 1, 2 and 3 reference polio strains grown in Vero monkey kidney cells have been advocated as a replacement for OPV; however, TIPVs have weak immunogenicity and multiple boosts are required before peak neutralizing titers are reached. This study examined whether the incorporation of the novel polysaccharide adjuvant, Advax-CpG, could boost the immunogenicity of two TIPV vaccines, (i) a commercially available polio vaccine (IPOL®, Sanofi Pasteur) and (ii) a new TIPV formulation developed by Statens Serum Institut (SSI). Mice were immunized intramuscularly based on recommended vaccine dosage schedules and serum antibody titers were followed for 12 months post-immunization. Advax-CpG significantly enhanced the long-term immunogenicity of both TIPV vaccines and had at least a 10-fold antigen dose-sparing effect. An exception was the poor ability of the SSI TIPV to induce serotype type 1 neutralizing antibodies. Immunization with monovalent IPVs suggested that the low type 1 response to TIPV may be due to antigen competition when the type 1 antigen was co-formulated with the type 2 and 3 antigens. This study provides valuable insights into the complexity of the formulation of multivalent polio vaccines and supports the further development of adjuvanted antigen-sparing TIPV vaccines in the fight to eradicate polio.

scholarly journals New Strains Intended for the Production of Inactivated Polio Vaccine at Low-Containment After Eradication

2015 ◽  
Vol 11 (12) ◽  
pp. e1005316 ◽  
Author(s):  
Sarah Knowlson ◽  
John Burlison ◽  
Elaine Giles ◽  
Helen Fox ◽  
Andrew J. Macadam ◽  
...  
Keyword(s):  
Inactivated Polio Vaccine ◽  
Polio Vaccine

scholarly journals Impact of Maternal Antibody on the Immunogenicity of Inactivated Polio Vaccine in Infants Immunized With Bivalent Oral Polio Vaccine: Implications for the Polio Eradication Endgame

2018 ◽  
Vol 67 (suppl_1) ◽  
pp. S57-S65 ◽  
Author(s):  
James T Gaensbauer ◽  
Chris Gast ◽  
Ananda S Bandyopadhyay ◽  
Miguel O’Ryan ◽  
Xavier Saez-Llorens ◽  
...  
Keyword(s):  
Oral Polio Vaccine ◽  
Polio Eradication ◽  
Maternal Antibody ◽  
Inactivated Polio Vaccine ◽  
Polio Vaccine

scholarly journals Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, following vaccination in children at 2, 4, 6 and at 15–18 months

Vaccine ◽  
2020 ◽  
Vol 38 (21) ◽  
pp. 3780-3789
Author(s):  
Xavier Sáez-Llorens ◽  
Birgit Thierry-Carstensen ◽  
Lina Saem Stoey ◽  
Charlotte Sørensen ◽  
Henrik Wachmann ◽  
...  
Keyword(s):  
Inactivated Polio Vaccine ◽  
Polio Vaccine

scholarly journals Factors associated with the utilization of inactivated polio vaccine among children aged 12 to 23 months in Kalungu District, Uganda

2020 ◽  
Vol 35 (Supplement_1) ◽  
pp. i30-i37
Author(s):  
Mirembe Rachel Faith ◽  
Babirye Juliet ◽  
Nathan Tumuhamye ◽  
Tumwebaze Mathias ◽  
Emma Sacks
Keyword(s):  
Health Care Providers ◽  
Health Workers ◽  
Oral Polio Vaccine ◽  
Systematic Sampling ◽  
Care Providers ◽  
Cross Sectional ◽  
Inactivated Polio Vaccine ◽  
Factors Associated ◽  
Polio Vaccine ◽  
Eradication Strategy

Abstract Uganda officially introduced the inactivated polio vaccine (IPV) in May 2016 as part of the polio eradication strategy and integrated it into its routine immunization programme in addition to the oral polio vaccine. The current coverage stands at 60% as of July 2017. We therefore aimed to determine factors associated with the uptake of IPV among children in Kalungu District so as to inform the implementation of the vaccine policy. A community-based cross-sectional study was conducted among caregivers of 406 eligible children aged 12–23 months through multi-stage systematic sampling and a standardized semi-structured questionnaire. Nine key informant interviews were conducted through purposive selection of health care providers and members of Village Health Teams (VHTs) based on their expertize. Modified Poisson regression and thematic content analysis were used to determine factors significant to IPV uptake among children. 71% of sampled children aged 12–23 months had received IPV in Kalungu District. The survey found that being encouraged by health workers and VHTs was significant to children’s uptake of IPV (Adjusted PR 1.24, 95% CI; 1.22–3.47). Distance to the immunization point (Adjusted PR 0.32,95% CI; 0.16–0.62) and caregiver’s education level (Adjusted PR 1.16,95% CI; 1.05–2.22) were also associated with IPV uptake. Qualitative findings from health workers and VHT members further confirmed the perception that distance to the immunization post was important, and VHTs also stated that being encouraged by health workers was critical to IPV uptake. The current prevalence of IPV uptake among children aged 12–23 months in Kalungu is 71%, higher than the last reported national coverage (60%), though still below the recommended national coverage of 95%. Efforts should be focused on sensitization of caregivers through health workers and VHTs. Immunization outreach should be strengthened so as to bring services closer to patients.

Sign in / Sign up

Export Citation Format

Share Document